Close Menu

This week in PLoS Genetics, an international team led by investigators at the National Human Genome Research Institute reports evidence to suggest that loss-of-function mutations in Atad5 — the human ortholog of yeast Elg1 — "are sufficient to cause genomic instability and tumorigenesis." The NHGRI-led team found that the heterozygous Atad5+/m mice they generated "displayed high levels of genomic instability in vivo," while Atad5+/m mouse embryonic fibroblasts showed "molecular defects in PCNA deubiquitination in response to DNA damage, as well as DNA

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The US Food and Drug Administration is to announce stricter standards for emergency authorizations of SARS-CoV-2 vaccines, reports the Washington Post.

The Associated Press reports Johnson & Johnson is starting a late-stage clinical trial of its candidate SARS-CoV-2 vaccine.

Bloomberg reports the budget of Operation Warp Speed is actually $18 billion, higher than the number typically cited.

In Genome Research this week: genomic analysis reveals role of super-spreaders in SARS-CoV-2, epigenetic drivers of cancer, and more.